利拉鲁肽(Liraglutide) - 药物靶点：GLP-1R_在研适应症：肥胖，超重，2型糖尿病_专利_临床

概要

基本信息

药物类型

重组多肽

别名

Liraglutide (Genetical Recombination)、Liraglutide Recombinant、Saxenda

+ [20]

靶点

GLP-1R

作用方式

激动剂

作用机制

GLP-1R激动剂(胰高血糖素样肽-1激动剂)

治疗领域

内分泌与代谢疾病神经系统疾病泌尿生殖系统疾病+ [1]

在研适应症

非在研适应症

原研机构

在研机构

Izmir Ekonomi ÜniversitesiNovo Nordisk, Inc.

+ [4]

非在研机构-

权益机构-

最高研发阶段批准上市

首次获批日期

欧盟 (2009-06-30),

2型糖尿病

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构/序列

Sequence Code 50953

来源: *****

关联

525

项与利拉鲁肽相关的临床试验

NCT07337174

/ Not yet recruiting临床1期

A Randomized, Open-label, Single Dose, Two-way, Crossover, Phase 1 Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetics After Subcutaneous Injection of HUC2-676 or HUC2-676-R in Healthy Adult Subjects

The trial uses a randomized, open-label, single-dose administration per period, and a 2 x 2 crossover design where subjects receive both treatments sequentially with a washout.

开始日期2026-01-25

申办/合作机构

Huons Co., Ltd.

NCT07301437

/ Not yet recruiting临床4期IIT

A Real-world Study of Liraglutide Alone and in Combination With Orlistat for Weight Loss in Overweight/Obese Patients.

To evaluate the differences in weight loss between liraglutide monotherapy and combined with orlistat in overweight/obese patients.

开始日期2026-01-01

申办/合作机构-

ChiCTR2500113481

/ Not yet recruiting早期临床1期IIT

The exploration of the efficacy and possible mechanisms of paroxetine combined with liraglutide in the treatment of depression associated with obesity.

开始日期2025-11-28

申办/合作机构

东南大学附属中大医院

100 项与利拉鲁肽相关的临床结果

登录后查看更多信息

100 项与利拉鲁肽相关的转化医学

登录后查看更多信息

100 项与利拉鲁肽相关的专利（医药）

登录后查看更多信息

3,840

项与利拉鲁肽相关的文献（医药）

2026-12-01·MOLECULAR BIOLOGY REPORTS

Mechanisms and therapeutic strategies of ferroptosis in Diabetic-Associated Cognitive Dysfunction: focus on the crosstalk with apoptosis, autophagy, and pyroptosis

Review

作者: Jiang, Yayi ; Zhou, Jianlong ; Yue, Rensong ; Shi, Wenxiang

Diabetes-associated cognitive dysfunction (DACD), a serious central nervous system complication of diabetes mellitus, poses a heavy global burden due to its intricate pathogenesis and lack of effective therapies. Mounting evidence identifies programmed cell death (PCD) as a pivotal driver of DACD progression. This review systematically elaborates on the molecular mechanisms of various PCD modalities (including apoptosis, autophagy, pyroptosis, and ferroptosis) in DACD, with a particular focus on the role of ferroptosis as a core pathogenic mechanism. Hyperglycemia disrupts cerebral iron homeostasis, induces mitochondrial dysfunction and oxidative stress, leading to inhibition of glutathione peroxidase 4 (GPX4) activity and accumulation of lipid peroxides. This cascade ultimately triggers ferroptosis in neurons, glial cells, and the blood-brain barrier, resulting in impaired synaptic plasticity and cognitive decline. Furthermore, the review delineates the complex interactive regulatory network between ferroptosis and other PCD forms (e.g., autophagy, pyroptosis), which can converge into the coordinated cell death program of PANoptosis. Intervention strategies targeting ferroptosis, such as iron chelators (deferoxamine), antioxidants (N-acetylcysteine), GPX4 activators, natural products (resveratrol, curcumin), repurposed traditional medicines (liraglutide, metformin), and non-pharmaceutical interventions (exercise, electroacupuncture), have demonstrated significant potential in improving cognitive function in preclinical models. This review aims to provide novel insights into the pathophysiology of DACD and establish a theoretical foundation for developing precise therapeutic strategies centered on targeting ferroptosis.

2026-04-01·JOURNAL OF NUTRITIONAL BIOCHEMISTRY

Olive-derived elenolic acid surpasses metformin and rivals liraglutide in managing blood glucose and obesity in a mouse model of type 2 diabetes

Article

作者: Cao, Xinyi ; Vaughan, Reagan ; Kale, Balaji ; Rachi, Md Abu T ; Silte, Abeje ; Zhang, Yan ; Rainville, Jennifer ; Liu, Dongmin ; Hodes, Georgia E ; Xu, Bin ; Wang, Yao ; Alkhalidy, Hana

Obesity and type 2 diabetes (T2D) are among the most common metabolic diseases that are associated with increased risk of noncommunicable diseases globally. Elenolic acid (EA), derived from olives, was shown to possess potent acute effects on obesity and diabetes that were associated with increased gut hormone secretion. Here, we investigate the long-term effects of EA in two mouse models of obesity and diabetes. In diet-induced obese mice, oral administration of EA (50 mg/kg/day) for 7 weeks, normalized fasting blood glucose (from 176.6±4.5 mg/dL to 120.8±4.0 mg/dL), and restored glucose tolerance and insulin sensitivity to levels comparable to lean mice. These improvements were associated with increased circulating peptide YY and gastric inhibitory polypeptide concentrations, downregulation of hypothalamic agouti-related peptide (AgRP), reduced food intake (∼20%), and weight loss. Acutely, EA slowed gastric emptying rate by about 50% and increased glucagon like peptide-1 levels. In db/db mice, EA reduced non-fasting blood glucose from 459.0±51.1 mg/dL to 208.9±10.3 mg/dL, an effect comparable to liraglutide and greater than metformin. EA also lowered fasting blood glucose levels similar to liraglutide and significantly below those observed with metformin. Moreover, EA-treated mice exhibited less weight gain than those receiving either drug. These effects were accompanied by decreased AgRP expression and increased c-fos activation. These results suggest that EA is a novel, multi-target agent with therapeutic potential for treating T2D and obesity.

2026-04-01·CURRENT OPINION IN NEUROBIOLOGY

The challenges of experimental pharmacology in identifying novel treatments for Parkinson's disease

Review

作者: Huot, Philippe ; Teil, Margaux

An important part of the field of experimental pharmacology encompasses the study of the effects of molecules in animals. In the case of Parkinson's disease (PD), animal models have played an invaluable role in refining our understanding of the disease, in characterizing the effect of new compounds on the illness, and in bringing new treatments to the clinic. Indeed, it is now hardly conceivable that a drug would be tested in humans if several parameters pertaining to safety, toxicology, efficacy, etc. had not previously been evaluated in animal models. Quite unfortunately, efficacy in experimental models of PD does not necessarily guarantee positive clinical outcomes. In this article, which primarily focusses on the past five years, we review drugs that entered clinical trials for the treatment of levodopa-induced dyskinesia, parkinsonism, disease modification, and had previously been assessed in animal models of PD. The drugs discussed are buspirone, JM-010, befiradol, mesdopetam, foliglurax, dipraglurant, tavapadon, prasinezumab, cinpanemab, nilotinib, minzasolmin, exenatide, NLY01, liraglutide, lixisenatide, and semaglutide. For each molecule, we examine how previous preclinical studies succeeded or failed in predicting efficacy in clinical trials and discuss possible ways to optimize animal-model design and selection to maximize the probability of translational success.

1,288

项与利拉鲁肽相关的新闻（医药）

2026-01-27

·砍柴网

胰岛素龙头业绩韧性增长，通化东宝预计2025年净利润超12亿元

1月26日晚，通化东宝发布2025年业绩预盈公告，公司预计全年实现归属于上市公司股东的净利润约12.42亿元，扣除非经常性损益的净利润约4.02亿元。通化东宝表示，去年净利润大幅增长主要系转让厦门特宝生物工程股份有限公司部分股权产生投资收益所致。此外，国内市场方面，公司依托胰岛素集采中标优势，推动门冬、甘精等胰岛素类似物产品快速上量，市场份额迅速提升；同时，利拉鲁肽注射液与恩格列净片等产品同样取得良好增长，多品类协同发力，带动国内销售收入较上期大幅攀升。并且，公司国际化战略成效显著，出口收入增长明显。对于通化东宝的这份业绩答卷，市场分析人士认为，2025年是胰岛素接续集采后的首个完整年度，得益于集采红利逐步释放，公司业绩“触底反弹”，展现出强大的经营韧性。与此同时，公司加速出海与创新，构筑多维度竞争优势，为企业高质量发展注入持久动力。胰岛素产品快速放量作为国内胰岛素领域领军企业，新一轮集采为通化东宝产品的准入与放量按下了“加速键”，其中胰岛素类似物成为业绩增长的核心动力，全年销量同比增幅超100%，收入占比稳步提升，公司的产品结构实现从人胰岛素为主向人胰岛素、胰岛素类似物均衡发展的提升。根据医药魔方2025年前三季度销量数据，通化东宝人胰岛素及胰岛素类似物销量市场份额继续位列行业第二，仅次于诺和诺德；公司各类胰岛素市场份额均实现进一步提升，其中，人胰岛素产品市场占有率继续攀升至45.5%，稳居国内第一；甘精胰岛素市占率稳步提升至15.0%；门冬系列胰岛素市占率正迅速扩大。在出海方面，2025年，通化东宝海外业务收入保持快速增长态势，成为公司业绩的重要增长极，并且海外市场拓展取得突破，胰岛素产品获得海外5国上市许可，出海版图持续扩大。根据公司公告，在产品国际注册方面，公司胰岛素制剂与GLP-1产品均取得积极进展。在胰岛素类似物方面，门冬胰岛素美国BLA获得美国FDA受理,以及在多米尼加、印尼获批上市；甘精胰岛素在缅甸获批上市。在人胰岛素方面，分别在乌兹别克斯坦和尼加拉瓜获批上市；GLP-1类产品利拉鲁肽注射液通过哥伦比亚、巴西GMP审计，并在新兴市场秘鲁获批上市。对于进军国际市场，通化东宝核心竞争力在于稳定的产品品质、充足的产能保障以及多元化的产品矩阵。此外，公司对国际市场合作模式保持开放和共赢的思路，持续提升在国际市场的竞争力和品牌影响力，护航产品“出海”行稳致远。以创新药转型为战略核心近年来，糖尿病治疗用药市场发生着重大变革，通化东宝根据市场变化，审时度势，持续推动创新转型，加速推进核心潜力管线进程，持续拓宽产品边界。资料显示，2025年2月，通化东宝公布了其重点在研产品GLP-1/GIP双靶点受体激动剂（注射用THDBH120）的Ib期临床数据，优异的研究结果显示出公司GLP-1类创新产品研发竞争力。作为一类创新药，该药品市场需求潜力巨大，有望成为更长效兼具糖尿病和肥胖两项适应症的药物。2025年4月，公司完成了痛风双靶点XO/URAT1抑制剂（THDBH151片）一项关键II a期临床试验并获得临床试验总结报告，研究结果显示达到主要终点目标。2025年3月，德谷胰岛素利拉鲁肽注射液的III期临床试验完成首例受试者给药，公司已处于国内研发进展的第一梯队。2025年1月，依托考昔片获上市许可，标志公司业务正从糖尿病拓宽至更大的内分泌代谢疾病治疗领域。总体来看，通化东宝研发管线，其多款重磅产品包括赖脯25R胰岛素、超速效胰岛素、德谷胰岛素利拉鲁肽注射液、司美格鲁肽注射液均已挺进III期临床阶段，预计2026-2027年将迎来产品商业化爆发期，形成“老品种稳增长、新品种快突破”的良性发展格局，为中长期业绩增长提供强劲动能。值得一提的是，2024年8月，通化东宝成立的上海隆棵药业有限公司，工作场地位于上海张江，是公司为更远的未来锁定前沿技术突破的研发主体。据悉，隆棵是通化东宝“强化前端创新、完善管线梯队”战略的精准落子，这家科创型孵化平台核心定位是聚焦药品早期开发与临床前研究，主攻差异化、突破性、治愈性药物，为母公司的长期增长储备“前沿技术火种”，把对前瞻技术的判断，进一步融入到公司的未来版图中。目前，隆棵已有近4000平的试验场地，80多人的研发队伍，其中博士占比超20%，硕士占比超40%。隆棵经过1年时间的成长孵化已经布局了细胞药物、核酸药物、超长效蛋白药物、小分子创新药等不同药物类型，打造从“治疗”到“治愈”，从“日制剂”“周制剂”“月制剂”到“3月给药一次”“半年给药一次”的创新性颠覆性疗法。用人胰岛素稳坐国内市场第一的“基本盘”，到GLP-1/GIP双靶点药瞄准临床痛点的“潜力盘”，再到隆棵聚焦小分子、核酸、蛋白、细胞治疗的“未来盘”，通化东宝不断探索糖尿病及其他内分泌代谢治疗领域广大未被满足的临床需求，进一步丰富公司现有产品体系，为长远发展开拓广阔成长空间，致力于成为“内分泌领域创新医药研发的探索者和引领者”。雄关漫道真如铁而今迈步从头越。2025年恰逢公司成立四十周年，这一里程碑节点既是通化东宝深耕医药领域、铸就胰岛素龙头地位的沉淀总结，更是开启创新转型新征程的全新起点。未来，公司将坚守“自主创新，世界品牌”的初心使命，以四十年积淀的技术、渠道与品牌优势为根基，以业绩韧性为支撑，以创新转型为抓手，续写老牌药企的奋进篇章。

2026-01-27

·今日头条

通化东宝预计2025年净赚12.42亿胰岛素类似物销量翻倍驱动扭亏

> 1月26日晚，通化东宝药业股份有限公司发布2025年年度业绩预盈公告，预计实现归属于母公司所有者的净利润约12.42亿元，与上年同期亏损相比实现大幅扭亏为盈；扣除非经常性损益后净利润约4.02亿元，标志着主营业务已重回盈利轨道。这一业绩逆转并非偶然，而是胰岛素类似物产品销量同比增幅超100%的快速放量，叠加海外业务收入强劲增长共同驱动的结果。 1. 业绩反转：从亏损到预盈12.42亿通化东宝的业绩预告显示，公司预计2025年实现归属于母公司所有者的净利润约12.42亿元，扣非净利润约4.02亿元，均较上年同期扭亏为盈。业绩大幅回升主要得益于主营业务与资本运作的双轮驱动： - **国内市场方面**，公司依托胰岛素集采中标优势，推动门冬、甘精等胰岛素类似物产品快速上量，市场份额迅速提升；同时，利拉鲁肽注射液与恩格列净片等产品同样取得良好增长，多品类协同发力，带动国内销售收入较上年同期大幅攀升。 - **非经常性损益方面**，转让厦门特宝生物工程股份有限公司股权产生显著收益，对净利润贡献较大。 2. 胰岛素放量：销量翻番与集采红利胰岛素类似物产品成为通化东宝2025年业绩增长的核心引擎。报告期内，公司胰岛素类似物产品**全年销量同比增幅超100%**，收入占比稳步提升，推动产品结构从以人胰岛素为主向人胰岛素与胰岛素类似物均衡发展转型。市场份额表现亮眼，根据医药魔方2025年前三季度销量数据： - 人胰岛素市占率攀升至**45.5%**，稳居国内第一。 - 甘精胰岛素市占率稳步提升至**15.0%**。 - 门冬系列胰岛素市占率处于快速扩大阶段。集采政策是放量的关键催化剂。根据胰岛素专项集采接续采购规则，公司额外获得全国集采二次分配量中的30%以上，约**1000万支**，叠加签约基础量约3500万支，本次集采公司协议签约量约**4500万支**，较首次胰岛素集采约2600万支的协议签约量增长了近2000万支。公司依托集采中标优势，快速推动医院准入与销售上量，成功实现“以量补价”。 3. 海外突破：收入高增与注册加速国际化战略已成为通化东宝业绩的重要增长极。继2024年海外收入突破亿元大关、同比增长近**80%**后，2025年公司海外收入延续强劲增长势头，产品出海版图持续扩大。在产品国际注册方面，公司取得多项突破： - **胰岛素类似物**：门冬胰岛素美国BLA获得美国FDA受理；门冬胰岛素注射液在多米尼加、印尼获批上市；甘精胰岛素注射液在缅甸获批上市。 - **人胰岛素**：精蛋白人胰岛素混合注射液（30R）在乌兹别克斯坦获批上市；精蛋白人胰岛素注射液在尼加拉瓜获批上市。 - **GLP-1产品**：利拉鲁肽注射液获哥伦比亚GMP证书，通过巴西GMP现场审计，并在秘鲁获批上市。这些进展构建起覆盖欧美、东南亚、拉美等多区域的销售网络，为后续海外市场放量奠定基础。 4. 非经常性收益：13亿转让款助力研发非经常性损益对净利润贡献显著。2025年7月，通化东宝完成了与西藏信托有限公司的股份协议转让，转让特宝生物**5.70%的股权**，转让价款总额为**13.01亿元**。转让完成后，公司持有特宝生物的股份比例由16.03%降至10.33%。 > 通化东宝表示，此次转让是基于公司持续深化创新转型发展战略的长远需要，有利于回笼资金，提高资产使用效率，集中力量向创新型药企发展，为公司布局创新药提供资金支持。这笔资金将用于创新药研发，如司美格鲁肽、GLP-1/GIP双靶点药物等项目，以推动公司高质量、可持续发展。 5. 研发管线：创新药布局未来增长通化东宝的研发创新稳步推进，多个项目在2025年取得临床进展： - **司美格鲁肽**：2025年6月顺利完成III期临床试验所有受试者的末次给药访视，目前已完成数据库锁定，正按计划开展试验总结工作。 - **德谷胰岛素利拉鲁肽注射液**：2025年3月完成III期临床试验首例受试者给药，目前已完成全部受试者入组。 - **GLP-1/GIP双靶点受体激动剂（注射用THDBH120）**：2025年2月获得降糖和减重Ib期临床试验积极的顶线结果；减重适应症II期临床试验已完成受试者入组。 - **其他进展**：XO/URAT1双靶点抑制剂（THDBH151片）IIa期临床试验达到主要终点；痛风化学口服药物依托考昔片已获得上市许可。这些管线覆盖糖尿病、减肥、痛风等内分泌代谢疾病，为公司长期增长提供动力。 6. 行业视角：国产替代与竞争格局在国产替代趋势下，通化东宝的市场地位逐步巩固。2025年，公司在中国治疗糖尿病用医药制剂市场的占有率约**8.5%**，并在基层医疗市场具备较强渗透能力。行业竞争格局中，外资企业如诺和诺德、赛诺菲、礼来仍占据高端市场优势，合计份额超过70%，但本土企业正通过集采和创新加速突围。通化东宝的结构性转变显著：2025年第三季度，胰岛素类似物的收入规模正式超越传统人胰岛素业务，成为产品升级的关键里程碑。公司毛利率达**71.89%**，盈利指标大幅改善。未来，公司计划进一步夯实国内胰岛素业务基本盘，深化国际化战略，并强化创新研发，以打造全价值链竞争力。

财报生物类似药带量采购引进/卖出

2026-01-27

·nanexa.com

Nanexa Announces Breakthrough Preclinical Data Demonstrating Exceptional Pharmacokinetic Profile for Monthly Semaglutide Formulation

27 January, 2026 - Regulatory Download attachment Nanexa’s atomic layer deposition (ALD) platform PharmaShell® demonstrably improves the pharmacokinetic profile of semaglutide injections. Significantly smoother plasma concentration curve could mitigate many common side effects of GLP-1 drugs. Less frequent dosing and improved adherence are key selling points for the next generation of GLP-1s, and reinforce Nanexa’s ability to secure new commercial partnerships. Nanexa AB today announces exceptional preclinical results for its long-acting semaglutide formulation developed using the company’s proprietary PharmaShell® drug delivery platform. PharmaShell encases active pharmaceutical ingredients at the atomic level in a highly protective, extremely thin film coating (approximately 30 nm thick) of slow-dissolving non-toxic inorganic oxides. Recent preclinical studies demonstrate an extraordinary pharmacokinetic (PK) profile, indicating a very low ratio between the maximum and minimum plasma concentration over the dosing interval following once-monthly subcutaneous administration. The plasma concentration is significantly more stable than that typically achieved with weekly administration of the marketed product Wegovy® (semaglutide). Breakthrough PK Profile with Potential to Reduce Gastrointestinal Side Effects A key hallmark of the new formulation is its low initial peak – a feature considered critical in reducing gastrointestinal (GI) adverse events commonly associated with GLP-1 therapies. By avoiding the sharp plasma concentration spikes often linked to nausea and other GI symptoms, Nanexa’s formulation may offer a more tolerable initiation and maintenance profile for patients. The preclinical results show clear dose-linearity, and significantly improved bioavailability compared with Nanexa’s earlier liraglutide formulations. Improved tolerability is strongly linked to improved adherence, which is a key issue associated with GLP-1 therapies. Strategic Shift: From Liraglutide to Semaglutide With these highly encouraging preclinical findings, Nanexa is shifting its development focus from liraglutide to semaglutide, reflecting the substantial therapeutic and commercial opportunity for long-acting GLP-1 treatments. The advancement of this semaglutide program builds directly on the clinical Phase 1 data from Nanexa’s liraglutide program, presented in 2025, which provided key insights into PharmaShell® performance in humans. Those findings enabled refined modelling, improved formulation strategies, and faster advancement for Nanexa toward clinical readiness for semaglutide. “These latest results represent a major milestone for Nanexa,” said David Westberg, CEO of Nanexa. “Demonstrating such a long release profile and low ratio between the maximum and minimum plasma concentration for monthly administration is exceptional and highlights how powerful the PharmaShell® technology can be for complex molecules like semaglutide. We are excited about this data which will strengthen our position to secure commercial partnerships.” For additional information, please contact: David Westberg – CEO, Nanexa AB (publ) Phone: +46 70 942 83 03 Email: david.westberg@nanexa.se www.nanexa.com Richard Hayhurst – Co-founder, 59 North Communications Phone: +447711 821527 Email: richard.hayhurst@59north.bio The company’s Certified Adviser is Tapper Partners AB. About Nanexa AB (publ) Nanexa is bringing the control, precision and versatility of Atomic Layer Deposition (ALD) technology to drug formulation. The company’s proprietary PharmaShell® platform is a unique drug delivery system that enables a high drug load, thus low injection volume, creating a new generation of ‘super generic’ formulations that will provide greater convenience and reduce costs in the treatment of conditions such as metabolic diseases like type 2 diabetes and obesity, hematology/oncology, cardiovascular disorders, psychiatry, and many others. Nanexa develops its own products and also has collaboration agreements with several pharma companies, including the latest license and option agreement with Moderna. Nanexa’s share is listed on Nasdaq First North Growth Market in Stockholm (NANEXA). Attachments Nanexa Announces Breakthrough Preclinical Data Demonstrating Exceptional Pharmacokinetic Profile for Monthly Semaglutide Formulation

临床1期引进/卖出临床结果

100 项与利拉鲁肽相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	利拉鲁肽	A10BJ02	DB06655

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
肥胖	美国	Novo Nordisk, Inc.	2014-12-23
超重	美国	Novo Nordisk, Inc.	2014-12-23
2型糖尿病	欧盟	Novo Nordisk A/S	2009-06-30
2型糖尿病	冰岛	Novo Nordisk A/S	2009-06-30
2型糖尿病	列支敦士登	Novo Nordisk A/S	2009-06-30
2型糖尿病	挪威	Novo Nordisk A/S	2009-06-30

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
脑血管疾病	临床3期	德国	Novo Nordisk A/S	2020-11-01
慢性心力衰竭	临床3期	德国	Novo Nordisk A/S	2020-11-01
冠状动脉疾病	临床3期	德国	Novo Nordisk A/S	2020-11-01
外周血管疾病	临床3期	德国	Novo Nordisk A/S	2020-11-01
多囊卵巢综合征	临床3期	美国	Novo Nordisk A/S	2018-09-26
暴食症	临床3期	美国	Novo Nordisk A/S	2017-09-29
普拉德-威利综合症	临床3期	美国	Novo Nordisk A/S	2015-11-09
普拉德-威利综合症	临床3期	澳大利亚	Novo Nordisk A/S	2015-11-09
普拉德-威利综合症	临床3期	加拿大	Novo Nordisk A/S	2015-11-09
普拉德-威利综合症	临床3期	法国	Novo Nordisk A/S	2015-11-09

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03948347 (LAMP, Pubmed \| JAMA Intern Med) 人工标引	临床3期	2型糖尿病 \| 短暂性脑缺血发作 \| 急性缺血性卒中	636	Liraglutide	獵鹽遞膚鹽積膚範鏇獵(鹹艱繭鹽襯鬱餘獵廠窪) = 鬱壓夢鬱繭構簾糧膚顧願衊壓艱構蓋簾壓窪廠 (廠蓋齋蓋齋顧願觸膚憲 ) 更多	积极	2025-11-03
				Control	獵鹽遞膚鹽積膚範鏇獵(鹹艱繭鹽襯鬱餘獵廠窪) = 簾繭獵鹽艱簾廠糧襯襯願衊壓艱構蓋簾壓窪廠 (廠蓋齋蓋齋顧願觸膚憲 ) 更多
NCT03260881 (CTgov)	临床4期	2型糖尿病 \| 冠心病	38	liraglutide (Study Group)	願製遞窪鹹鹹壓憲鏇獵(積蓋艱願壓糧選鬱醖蓋) = 願醖夢繭選鬱襯鑰窪觸窪窪顧齋壓鏇鹹憲觸鹹 (夢顧襯鑰餘憲鬱齋糧膚, 0.60) 更多	-	2025-07-08
				placebo (Control Group)	願製遞窪鹹鹹壓憲鏇獵(積蓋艱願壓糧選鬱醖蓋) = 積淵齋鏇餘衊選鹽夢構窪窪顧齋壓鏇鹹憲觸鹹 (夢顧襯鑰餘憲鬱齋糧膚, 2.3) 更多
NCT02516657 (CTgov)	临床3期	1型糖尿病	5	Liraglutide	範積築鹽鏇憲顧壓鏇簾(憲範衊廠選繭壓獵願鹹) = 製襯醖鹽襯齋範構觸蓋鏇膚艱鹽製淵鏇鹽鏇製 (選齋膚鹽鬱衊範簾醖選, 35) 更多	-	2025-04-20
NCT04881110 (STARDUST, CTgov)	临床4期	2型糖尿病 \| 外周动脉疾病	60	Liraglutide (Liraglutide Group)	築築顧壓獵範醖艱窪餘(構蓋簾獵憲構窪艱範蓋) = 願願淵蓋廠糧淵選醖醖觸蓋蓋夢膚醖簾糧遞簾 (襯製壓網築構窪鏇夢構, 5.9) 更多	-	2025-03-03
				Control (Control Group)	築築顧壓獵範醖艱窪餘(構蓋簾獵憲構窪艱範蓋) = 艱艱願糧醖網壓餘觸餘觸蓋蓋夢膚醖簾糧遞簾 (襯製壓網築構窪鏇夢構, 4.8) 更多
ASCO_GU2025	临床3期	前列腺癌	-	GLP-1 receptor agonists (GLP-1RAs)	願膚範繭獵獵選鏇網鏇(範憲艱壓顧壓築鹽繭繭) = 窪襯窪獵壓憲齋蓋糧淵衊憲繭範繭膚壓範蓋構 (網網選齋繭齋鑰簾顧衊 )	不佳	2025-02-13
				Placebo/non-GLP-1 RA regimens	願膚範繭獵獵選鏇網鏇(範憲艱壓顧壓築鹽繭繭) = 遞膚憲鹽膚網糧鹹蓋製衊憲繭範繭膚壓範蓋構 (網網選齋繭齋鑰簾顧衊 )
Pubmed 人工标引	N/A	超重 \| 肥胖	15,491	Tirzepatide 15 mg once weekly	糧鏇鑰糧廠鹽鬱鏇選製(窪獵觸窪襯夢壓艱鏇顧) = 遞艱積鹽壓選蓋簾繭鏇蓋廠繭膚獵積簾廠糧鬱 (艱蓋醖膚襯構鹽壓繭繭 )	积极	2025-01-07
				Semaglutide 2.4 mg once weekly	糧鏇鑰糧廠鹽鬱鏇選製(窪獵觸窪襯夢壓艱鏇顧) = 醖淵遞淵觸鬱獵艱築襯蓋廠繭膚獵積簾廠糧鬱 (艱蓋醖膚襯構鹽壓繭繭 )
NCT02098395 \| NCT01836523 (ADJUNCT ONE and ADJUNCT TWO, Pubmed \| J Diabetes Sci Technol)	临床3期	1型糖尿病 C-peptide	-	Liraglutide 1.8 mg	鹽衊願醖願艱艱顧夢鬱(製襯積衊鬱壓鹹簾蓋積) = 壓膚夢醖衊鬱構築壓網衊簾壓製築衊鹽顧憲齋 (構蓋選蓋網醖範遞艱範 ) 更多	-	2024-12-24
				Liraglutide 1.2 mg	鹽衊願醖願艱艱顧夢鬱(製襯積衊鬱壓鹹簾蓋積) = 醖鏇鹹餘淵網糧衊醖蓋衊簾壓製築衊鹽顧憲齋 (構蓋選蓋網醖範遞艱範 ) 更多
NCT06439056 (NEWS)	临床1期	2型糖尿病	3	利拉鲁肽-NEX-22A	艱選繭壓齋壓鹹艱窪簾(範簾簾願齋鑰衊願齋築) = Clinical results have reached the endpoint 糧蓋顧範蓋艱鏇構製簾 (願觸鏇壓餘襯憲膚築糧 ) 更多	积极	2024-11-22
NCT04883346 (LBODP002, CTgov)	临床2期	肥胖	34	Liraglutide	鑰壓積膚憲襯壓廠夢廠 = 鏇製鹽製膚糧憲網範醖鬱築蓋範餘鬱餘醖糧齋 (淵鑰糧衊鹹鏇窪鏇窪襯, 膚蓋築鏇選憲餘繭憲鏇 ~ 製積築繭鑰廠淵糧鏇遞) 更多	-	2024-11-20
NCT01794143 (Pubmed \| PLoS One)	临床3期	2型糖尿病	-	Glargine	繭築蓋衊選選蓋構構繭(鹽衊築衊鹹築獵蓋鹹製) = 廠範衊蓋襯簾窪壓齋廠繭遞憲鏇網壓廠築積繭 (廠網艱廠廠壓簾蓋範顧 ) 更多	积极	2024-11-15
				Glimepiride	繭築蓋衊選選蓋構構繭(鹽衊築衊鹹築獵蓋鹹製) = 齋鹽淵艱糧顧鬱夢醖積繭遞憲鏇網壓廠築積繭 (廠網艱廠廠壓簾蓋範顧 ) 更多